A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) for Genome-Scale Analysis and Absolute Quantitation of Circulating MicroRNA Biomarkers

Abstract

The plasma levels of tissue-specific microRNAs can be used as diagnostic, disease severity and prognostic biomarkers for chronic and acute diseases and drug-induced injury. Thereby, the combination of diverse microRNAs into biomarker signatures using multivariate statistics seems especially powerful from the perspective of tissue and condition specific microRNA shedding into the plasma. Although next-generation sequencing (NGS) technology enables one to analyse circulating microRNAs on a genome-scale level, it suffers from potential biases (e.g., adapter ligation bias) and lacks absolute transcript quantitation as well as tailor-made quality controls. In order to develop a robust NGS discovery assay for genome-scale quantitation of circulating microRNAs, we first evaluated the sensitivity, repeatability and ligation bias of four commercially available small RNA library preparation protocols. The protocol from RealSeq Biosciences was selected based on its performance and usability and coupled with a novel panel of exogenous small RNA spike-in controls to enable quality control and absolute quantitation, thus ensuring comparability of data across independent NGS experiments. The established microRNA Next-Generation-Sequencing Discovery Assay (miND) was validated for its relative accuracy, precision, analytical measurement range and sequencing bias and was considered fit-for-purpose for microRNA biomarker discovery. Summarized, all these criteria were met, and thus, our analytical platform is considered fit-for-purpose for microRNA biomarker discovery from biofluids in the setting of any diagnostic, prognostic or patient stratification need. The established miND assay was tested on serum, cerebrospinal fluid (CSF), synovial fluid (SF) and extracellular vesicles (EV) extracted from cell culture medium of primary cells and proved its potential to be used across different sample types.

Circulating miRNAs Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis—the MiDeTe study

“…Library preparation was performed as described by Khamina et al ( 28 ) using RealSeq-Biofluids Plasma/Serum miRNA Library kit for Illumina sequencing (RealSeq Biosciences, Santa Cruz, US, Cat No. 600-00048-SOM) and miND spike-in controls (TAmiRNA, Austria, Cat No.…”

Effect of Anti-Osteoporotic Treatments on Circulating and Bone MicroRNA Patterns in Osteopenic ZDF Rats

“…Based on previous studies performed by Khamina et al [ 56 ], library preparation was performed using RealSeq-Biofluids Plasma/Serum miRNA Library kit for Illumina sequencing (RealSeq Biosciences, 600-00048; protocol 20181220_RealSeq-BF_CL) according to the manufacturer’s protocol. Briefly, 8.5 μL of extracted RNA was used as input.…”

Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectives

“…To achieve this goal, a detailed protocol has been developed by TransBioLine for plasma sample collection for the purpose of miRNA analysis (Schofield et al 2021). In addition, TransBio-Line members have established robust assays for identification and quantification of miRNAs (Khamina et al 2022). Although testicular toxicity is not in the scope of this project, the learnings will enable advancement of miRNA work in other areas such as testicular toxicity.…”